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Background: Cross-sectional observational studies have reported obesity and
cardiometabolic co-morbidities as important predictors of coronavirus disease 2019
(COVID-19) hospitalization. The causal impact of these risk factors is unknown
at present.
Methods: We conducted multivariable logistic regression to evaluate the observational
associations between obesity traits (body mass index [BMI], waist circumference [WC]),
quantitative cardiometabolic parameters (systolic blood pressure [SBP], serum glucose,
serum glycated hemoglobin [HbA1c], low-density lipoprotein [LDL] cholesterol, high-
density lipoprotein [HDL] cholesterol and triglycerides [TG]) and SARS-CoV-2 positivity
in the UK Biobank cohort. One-sample MR was performed by using the genetic risk
scores of obesity and cardiometabolic traits constructed from independent datasets
and the genotype and phenotype data from the UK Biobank. Two-sample MR was
performed using the summary statistics from COVID-19 host genetics initiative. Cox
proportional hazard models were fitted to assess the risk conferred by different genetic
quintiles of causative exposure traits.
Results: The study comprised 1,211 European participants who were tested positive
for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 387,079
participants who were either untested or tested negative between 16 March 2020 to 31
May 2020. Observationally, higher BMI, WC, HbA1c and lower HDL-cholesterol were
associated with higher odds of COVID-19 infection. One-sample MR analyses found
causal associations between higher genetically determined BMI and LDL cholesterol
and increased risk of COVID-19 (odds ratio [OR]: 1.15, confidence interval [CI]: 1.05–
1.26 and OR: 1.58, CI: 1.21–2.06, per 1 standard deviation increment in BMI and LDL
cholesterol respectively). Two-sample MR produced concordant results. Cox models
indicated that individuals in the higher genetic risk score quintiles of BMI and LDL were
more predisposed to COVID-19 (hazard ratio [HR]: 1.24, CI: 1.03–1.49 and HR: 1.37, CI:
1.14–1.65, for the top vs the bottom quintile for BMI and LDL cholesterol, respectively).
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Conclusion: We identified causal associations between BMI, LDL cholesterol and
susceptibility to COVID-19. In particular, individuals in higher genetic risk categories were
predisposed to SARS-CoV-2 infection. These findings support the integration of BMI into
the risk assessment of COVID-19 and allude to a potential role of lipid modification in
the prevention and treatment.
Keywords: obesity, lipid profile, mendelian randomization, COVID-19, SARS-CoV-2
INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the pathogen of coronavirus disease 2019 (COVID-19),
has inflicted a once-in-a-century pandemic. More than 7
million confirmed cases have been reported worldwide with
over 407,000 deaths as of June 9 (COVID-19 Map, 2020).
Although many countries have navigated past the peak of
the epidemic (“flattened the curve”), the viral transmission is
expected to continue in the communities for the foreseeable
future. Understanding the host factors influencing the disease
susceptibility is imperative in unraveling the disease biology
and risk stratification. Multiple observational studies have
reported that certain patient characteristics (e.g., age, male sex,
ethnicity) and comorbid conditions are associated with COVID-
19 susceptibility and worse outcomes (Collaborative et al., 2020;
Docherty et al., 2020; Li et al., 2020). In particular, elevated
body mass index (BMI), a widely used surrogate of obesity, has
emerged as an important risk factor for COVID-19 hospital
admission, disease severity and in-hospital mortality (Kalligeros
et al., 2020; Lighter et al., 2020; Palaiodimos et al., 2020; Simonnet
et al., 2020). Likewise, other important constituents of metabolic
syndrome namely diabetes and hypertension have been reported
to be associated with at least twofold higher risk of severe or fatal
COVID-19 (Kumar et al., 2020; Lippi et al., 2020). Nonetheless,
given the observational nature of previous COVID-19 studies,
the causal impact of obesity and cardiometabolic indices on
COVID-19 susceptibility has not been ascertained.
Mendelian randomization (MR) is an analytic technique that
uses genetic variants as instruments to estimate the causal
effect of an exposure risk factor on an outcome of interest
(Smith and Ebrahim, 2003). By leveraging on the Mendel’s
law of independent assortment, MR analyses overcome the
limitations of confounding, measurement errors and reverse
causation frequently encountered in observational studies.
Furthermore, it permits causal analysis in the settings where
traditional randomized-controlled trials are unfeasible due to
ethical or technical reasons. In this study, we examined
the causal relationship between obesity traits, quantitative
cardiometabolic biomarkers and COVID-19 susceptibility using
Mendelian randomization.
MATERIALS AND METHODS
Study Design
We performed multivariable regression analyses of observational
data, one-sample MR using individual-level genotype data from
the UK Biobank, and two-sample MR using the genome-
wide association data provided by COVID-19 host genetics
initiative (The COVID-19 Host Genetics Initiative, 2020) to
explore if obesity traits (BMI and waist circumference [WC])
and quantitative cardiometabolic parameters (systolic blood
pressure [SBP], serum glucose, serum glycated hemoglobin
[HbA1c]), low-density lipoprotein [LDL] cholesterol, high-
density lipoprotein [HDL] cholesterol and triglycerides [TG])
are causally associated with SARS-CoV-2 positivity (i.e., COVID-
19 diagnosis).
Data Sources
UK Biobank
The UK Biobank is a population-based cohort study of 500,000
individuals aged between 40 and 69 years at the time of initial
recruitment between 2006 and 2010. It has collected information
on health and lifestyle data, physical measurements, biological
samples, genotype and multi-modal imaging data (Sudlow et al.,
2015). We used the obesity and cardiometabolic measurements
taken at the baseline visit where available. Further information
on derivation of exposure variables and covariates is available in
Supplementary Methods.
From March 16, 2020, the UK Biobank has started releasing
COVID-19 test results of the study participants enabled by the
Bugbank project (Armstrong et al., 2020; Hilton et al., 2020). We
used the data downloaded on June 5, 2020 (the last test date in
the sample was May 31, 2020). As the test data was only available
for England at the time of analysis, only participants residing in
England were included in the analysis. Non-European ancestries
were excluded in order to improve homogeneity of the study
population and align with the genetic analyses.
This study was covered by the general ethical approval for UK
Biobank studies from the NHS National Research Ethics Service
on May 10, 2016 (Ref 16/NW/0274). The data underlying this
article are available from the UK Biobank1.
Variant Selection and Genetic Risk Score
Construction
We used the variant effect sizes from publicly available genome-
wide association meta-analyses conducted in non-UK Biobank
samples to avoid circular inferences or overestimation. The
following GWAS summary statistics were accessed: BMI and
BMI-adjusted WC data from the Genetic Investigation of
ANthropometric Traits (GIANT) consortium (Locke et al.,
2015; Shungin et al., 2015); fasting serum glucose and HbA1c
1http://www.ukbiobank.ac.uk/register-apply/
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data from the Meta-Analyses of Glucose and Insulin-related
traits Consortium (MAGIC) consortium (Manning et al., 2012;
Wheeler et al., 2017); serum LDL cholesterol, HDL cholesterol
and TG from the Global Lipids Genetic Consortium (GLGC)
(Willer et al., 2013); SBP from Evangelou et al. (2018). Further
information on each study was outlined in eMethods. We used
the plink (Purcell et al., 2007) software’s “–clump” command
with linkage disequilibrium (LD) r2 threshold of 0.01 to obtain
a set of uncorrelated variants at P < 5 × 10−8. This process
produced 77, 75, 250, 26, 45, 101, 125, 73 independent variants
for BMI, WC, SBP, serum glucose, HbA1c, LDL cholesterol, HDL
cholesterol, triglycerides, respectively (Supplementary Tables 1–
8). The weighted genetic risk score (GRS) for each exposure trait
was calculated by summing the product of the effect sizes and the
number of effect alleles across all selected variants.
Statistical Analysis
Observational Analysis
The participant characteristics stratified by COVID-19 test status
are presented as mean ± standard deviation or median and
interquartile range (IQR) for continuous variables and number
(percentage) for categorical variables. The inter-group differences
were compared by unpaired t-test, Mann-Whitney U test or
Fisher’s exact test.
The observational associations between obesity traits,
cardiometabolic parameters and SARS-CoV-2 positivity were
investigated by multivariable logistic regression adjusted for
age at recruitment, sex, multiple deprivation index, smoking
history, pre-existing cardiovascular disease, respiratory disease,
renal disease and dementia, previous malignancy and exposure-
specific additional adjustments. Exposure-specific adjustments
were performed to account for confounding by co-existing
risk factors while minimizing collinearity. These include
hypertension, dyslipidaemia and diabetes for obesity traits;
BMI, dyslipidaemia and diabetes for SBP; BMI, hypertension
and dyslipidaemia for glycemic traits; BMI, hypertension and
diabetes for lipid traits. We considered variance inflation factor
(VIF) >3 as an indicator of collinearity between covariates.
Mendelian Randomization
We applied the two-stage predictor substitution method using
polygenic risk scores for each phenotype data to perform one-
sample MR (Burgess, 2013). The one-sample MR analyses were
only adjusted for the first 5 principal components to minimize
the risk of collider bias. Summary-level genome-wide association
meta-analysis data from COVID-19 host genetics initiative
(The COVID-19 Host Genetics Initiative, 2020) were used to
perform two sample MR. Two-sample MR effect estimates for
each exposure trait were calculated by the inverse variance-
weighted (IVW) method. Additionally, we used the MR-Egger
and weighted median methods to evaluate the validity of genetic
instruments (Bowden et al., 2016; Burgess et al., 2016). We
assessed the presence of weak instrument bias (also known as
violation of relevance assumption in MR) by calculating the
F-statistic from the linear regression between GRS and measured
phenotypes (Davies et al., 2015). Other key assumptions
underpinning the MR analysis are: (i) the instrument is
independent of confounders (independence assumption) and (ii)
the instrument exerts its effect exclusively through the risk factor
of interest (exclusion restriction assumption). We tested these
assumptions to a limited extent by adjusting for all potential
confounders as utilized in the observational analysis in our MR
framework. We assessed the presence of horizontal pleiotropy
which would violate the exclusion restriction assumption by
conducting: (i) the MR-Egger intercept test and (ii) the MR-
PRESSO (Verbanck et al., 2018) (Mendelian Randomization
Pleiotropy RESidual Sum and Outlier) global test. As a sensitivity
analysis, we repeated one-sample MR procedures in a restricted
sample of individuals tested for SARS-CoV-2 to explore potential
biases introduced by asymptomatic or mildly symptomatic
participants who were never tested.
The causal effects were considered only if supported by
both one-sample and two-sample MR analyses. The effect sizes
are presented by odds ratio (OR) and robust 95% confidence
intervals (CI) per 1 standard deviation (SD) change in exposure.
We also fitted Cox proportional hazards models adjusted for age
at recruitment, sex and the first 5 genetic principal components
to evaluate the associations between the weighted GRSs of obesity
and cardiometabolic parameters and the risk of SARS-CoV-
2 infection. Proportional hazards assumption was checked by
assessing the Schoenfeld residuals. All analyses were conducted in
the R statistical computing environment (version 3.6.1) (R Core
Team, 2016). The two-sample MR analyses were conducted using
“MendelianRandomization” (Yavorska and Burgess, 2017) and
“TwoSampleMR” (Hemani et al., 2018) R package.
RESULTS
The clinical characteristics of the study cohort are presented in
Table 1. The study comprised 1,211 individuals tested positive for
SARS-CoV-2 and 387,079 individuals who were either untested
or tested negative between March 16, 2020 and May 31, 2020.
Participants with positive test were more likely to be older, male,
more deprived and had higher prevalence of cardiometabolic
risk factors and comorbidities. The F-statistics of the genetic risk
scores were 6491, 664, 7532, 1669, 7816, 26854, 26995, and 19746
for BMI, WC, SBP, serum glucose, HbA1c, LDL cholesterol, HDL
cholesterol and triglycerides, respectively. Large F-statistic values
(>10) indicated that the MR analyses were unlikely to be affected
by the weak instrument bias.
Relationship Between Obesity
Phenotypes and COVID-19 Susceptibility
In observational analyses, higher BMI and WC were associated
with higher odds of SARS-CoV-2 positivity (OR: 1.13 [CI:
1.07–1.20], OR: 1.15 [CI: 1.08–1.23], for 1 SD increment in
BMI and WC, respectively) (Table 2). One-sample MR analyses
indicated a causal relationship between higher BMI and increased
odds of positive test (OR: 1.15 [CI: 1.05–1.26]) but WC
was not causally associated with COVID-19 status. The MR
analyses additionally controlled for other covariates included
in the observational analyses did not attenuate the findings
(Supplementary Table 9). Two sample MR by IVW method
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TABLE 1 | Demographic and clinical characteristics.
Variable Total Untested/negative Positive P
n 388,290 387,079 1,211
Age at recruitment, mean (SD), years 56.6 (8.0) 56.6 (8.0) 57.1 (9.2) 0.049
Male, No. (%) 175,535 (45) 174,895 (45) 640 (53) <0.001
Multiple deprivation index quintiles, No. (%) <0.001
1 (most affluent) 75,826 (20) 75,644 (20) 182 (16)
2 75524 (20) 75,351 (20) 173 (15)
3 75437 (20) 75,241 (20) 196 (17)
4 75629 (20) 75,354 (20) 275 (24)
5 (most deprived) 75513 (20) 75,169 (20) 344 (29)
Hypertension, No. (%) 130582 (34) 130,034 (34) 548 (45) <0.001
Dyslipidaemia, No. (%) 114236 (29) 113,801 (29) 435 (36) <0.001
Diabetes mellitus, No. (%) 27015 (7) 26,835 (7) 180 (15) <0.001
Smoking status, No. (%) <0.001
Never 210836 (54) 210,288 (54) 548 (45)
Previous 139318 (36) 138,795 (36) 523 (43)
Current 38136 (10) 37,996 (10) 140 (12)
Cardiovascular disease, No. (%) 35986 (9) 35,789 (9) 197 (16) <0.001
Respiratory disease, No. (%) 63029 (16) 62,750 (16) 279 (23) <0.001
Renal disease, No. (%) 15859 (4) 15,735 (4) 124 (10) <0.001
Previous malignancy, No. (%) 67852 (18) 67,618 (18) 234 (19) 0.097
Dementia, No. (%) 1317 (0.3) 1,270 (0.3) 47 (4) <0.001
Body mass index, mean (SD), kg/m2 27.3 (4.7) 27.3 (4.7) 28.7 (5.4) <0.001
Waist circumference, mean (SD), cm 90.1 (13.4) 90.1 (13.4) 94.3 (14.4) <0.001
Systolic blood pressure, mean (SD), mmHg 141.0 (20.5) 141.0 (20.5) 143.1 (21.8) <0.001
Fasting glucose, median [IQR], mmol/L 4.9 [4.6, 5.3] 4.9 [4.6, 5.3] 5.0 [4.6, 5.4] 0.221
HbA1c, median [IQR], mmol/mol 35.1 [32.7, 37.6] 35.1 [32.7, 37.6] 35.6 [33.1, 38.7] <0.001
LDL cholesterol, mean (SD), mmol/L 3.6 (0.9) 3.6 (0.9) 3.5 (0.9) <0.001
HDL cholesterol, mean (SD), mmol/L 1.5 (0.4) 1.5 (0.4) 1.4 (0.3) <0.001
Triglycerides, mean (SD), mmol/L 1.7 (1.0) 1.7 (1.0) 1.9 (1.1) <0.001
HbA1c, glycated hemoglobin; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SD, standard deviation; IQR, interquartile range.
confirmed the causal association between BMI and COVID-19
identified in one-sample analysis (Table 3 and Supplementary
Figure 1). Analyses by MR-Egger and weighted median methods
produced directionally concordant results (Supplementary
Table 10). There was no evidence of substantial horizontal
pleiotropy as indicated by Egger intercept test and MR-PRESSO
global test (Egger intercept P = 0.459, MR-PRESSO P = 0.557).
Sensitivity analyses in a restricted cohort of individuals tested for
SARS-CoV-2 (positive = 1,211, negative = 4,086) produced an
MR estimate for BMI in a consistent effect direction compared
to the main results (Supplementary Table 11).
Relationship Cardiometabolic Indices
and COVID-19 Susceptibility
The observational analysis indicated that higher HbA1c and
lower serum HDL-cholesterol were associated with higher odds
of SARS-CoV-2 positive result (OR: 1.04 [CI: 1.004–1.09];
OR: 0.85 [CI: 0.78–0.92] for 1 SD increment in HbA1c and
HDL cholesterol, respectively) (Table 2). After adjusting for
potential confounders, SBP, fasting glucose, LDL-cholesterol and
triglycerides were not associated with COVID-19 status. In
contrast, in one-sample MR analysis, higher LDL cholesterol
was associated with higher odds of SARS-CoV-2 infection
(OR: 1.58 [CI: 1.21–2.06]). No other causal relationship
was identified between other cardiometabolic parameters and
COVID-19 status. Additional adjustment of one-sample MR with
observation covariates yielded similar results (Supplementary
Table 9). These findings were also supported by two-sample MR
results (Table 3). There was no evidence of horizonal pleiotropy
(Egger intercept P = 0.899, MR-PRESSO P = 0.741). The MR
analysis in a restricted sample of individuals who had received
testing supported the causal association between LDL cholesterol
and COVID-19 susceptibility (OR: 1.74 [CI: 1.22–12.47]).
Polygenic Prediction of COVID-19 Risk
Genetically determined BMI was associated with higher risk of
SARS-CoV-2 infection with the greatest risk observed in the top
quintile of BMI-GRS (Hazard ratio [HR]: 1.24 [CI: 1.03–1.49]
compared to the lowest quintile) (Figure 1). Likewise, genetically
higher exposure to LDL cholesterol was related to increased risk
of COVID-19 (HR: 1.37 [CI: 1.14–1.65] for the top quintile
vs the bottom quintile). Observationally, the same pattern of
relationship was identified only for BMI.
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TABLE 2 | Observational and one-sample MR analysis.
Trait Observational effect size Observational 95% CI Observational P-value MR effect size MR 95% CI MR P-value
BMI 1.13 1.07–1.20 1.26 × 10−5 1.15 1.05–1.26 0.003
WC 1.15 1.08–1.23 1.91 × 10−5 1.06 0.95–1.18 0.270
SBP 0.99 0.93–1.06 0.863 1.02 1.00–1.04 0.111
Fasting glucose 1.04 0.99–1.10 0.090 0.73 0.33–1.61 0.434
HbA1c 1.04 1.004–1.09 0.031 0.98 0.92–1.04 0.519
LDL cholesterol 0.97 0.91–1.03 0.335 1.58 1.21–2.06 0.001
HDL cholesterol 0.85 0.78–0.92 3.17 × 10−5 1.03 0.57–1.85 0.918
Triglycerides 0.99 0.93–1.05 0.748 1.17 0.90–1.51 0.243
Effect sizes represent odds ratio for every 1 standard deviation increment in exposure trait. The standard deviations are: 4.7 kg/m2, 13.4 cm, 20.5 mmHg, 1.2 mmol/L,
6.3 mmol/mol, 0.87 mmol/L, 0.38 mmol/L and 1.0 mmol/L, for BMI, WC, SBP, fasting glucose, HbA1c, LDL cholesterol, HDL cholesterol and triglycerides, respectively.
BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure, HbA1c, glycated hemoglobin; LDL, low-density lipoprotein; HDL, high-density lipoprotein;
CI, confidence interval; MR, Mendelian randomization.
TABLE 3 | Two-sample MR analysis.
Trait IVW effect size IVW 95% CI IVW P-value Egger intercept Egger intercept P-value MR-PRESSO global test P-value
BMI 1.80 1.28–2.54 0.001 0.013 0.129 0.557
WC 1.25 0.86–1.79 0.238 0.004 0.772 0.817
SBP 0.79 0.52–1.20 0.278 0.00003 0.966 0.674
Fasting glucose 0.78 0.51–1.19 0.253 −0.019 0.111 0.791
HbA1c 0.26 0.01–8.47 0.446 0.022 0.024 0.813
LDL cholesterol 1.20 1.06–1.37 0.006 0.001 0.899 0.741
HDL cholesterol 1.03 0.84–1.25 0.803 −0.01 0.144 0.875
Triglycerides 1.10 0.79–1.53 0.578 0.002 0.876 0.939
Effect sizes represent odds ratio for every 1 standard deviation increment in exposure trait.
BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure, HbA1c, glycated hemoglobin; LDL, low-density lipoprotein; HDL, high-density lipoprotein;
IVW, inverse variance weighted; CI, confidence interval; MR, Mendelian randomization.
FIGURE 1 | Association between measured and genetic BMI, LDL cholesterol, and SARS-COV-2 infection. SARS-COV-2, severe acute respiratory syndrome
coronavirus 2; BMI, body mass index; LDL, low-density lipoprotein; HR, hazard ratio; CI, confidence interval.
DISCUSSION
In this study, we examined the causal relationship between
obesity traits, quantitative cardiometabolic biomarkers and
COVID-19 susceptibility using Mendelian randomization.
We identified a causal relationship between BMI and LDL
cholesterol and susceptibility to COVID-19. In contrast,
WC and other quantitative cardiometabolic markers such
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as SBP, serum glucose, HbA1c, HDL and triglycerides,
were not causally linked to increased risk of SARS-CoV-
2 infection. The highest risk was observed in individuals
belonging to the top genetic risk quintiles of BMI and
LDL cholesterol.
Recent observational data from China have identified that
age and obesity related complications such as hypertension and
type 2 diabetes mellitus may be risk factors for development
of severe COVID-19 (Shi et al., 2020). A high prevalence of
obesity in severe COVID-19 patients has also been observed
in recent studies (Caussy et al., 2020; Lighter et al., 2020;
Simonnet et al., 2020), with greater requirement for mechanical
ventilation in those who are in the overweight or obese
categories. However, these purely observational studies were
open to confounding despite attempts at adjustments for
potential known or measured factors. Our study attempted
to overcome the inherent limitations of observational data
by instrumental variable analysis using genetic variants
which are randomly allocated at conception. This approach
provided the evidence for causal linkage between obesity
and COVID-19 diagnosis while circumventing the issues
related to confounding, recall bias, measurement errors and
reverse causation.
There are a number of possible explanations for our
findings. Obesity has been associated with more severe
and prolonged disease as noted with previous epidemics
(Huttunen and Syrjänen, 2013; Honce and Schultz-Cherry,
2019). Obese patients are more likely to have reduced
and restrictive pulmonary function, which can subsequently
improve following weight reduction through bariatric surgery
(Copley et al., 2020). The immune response may be adversely
altered in obesity which could have deleterious effect on
the respiratory function. In particular interleukin-6 levels
and type 2 inflammation have been shown to be increased
in patients with obesity and metabolic syndrome, along
with abnormal secretion of adipokines and cytokines such
as interferon and TNF-a in individuals with abdominal
obesity (Huttunen and Syrjänen, 2013; Peters et al., 2016;
Zhang et al., 2017).
After controlling for potential confounders, LDL cholesterol
concentration was not found to be associated with COVID-19
in our observational analysis. This finding is contrary to recent
observational studies. A retrospective study from Wuhan, China,
of SARS-CoV-2 infected patients found that total cholesterol
and LDL levels were inversely associated with disease severity
(Wei et al., 2020). A different group from Wenzhou, China
also suggest in an observational study that those with the
infection had significantly lower total cholesterol, HDL and
LDL (Hu et al., 2020). It should be noted that both studies
reported cross-sectional inter-group differences without robust
adjustment for potential confounders. Conversely, a recent study
investigating the association between LDL cholesterol and risk
of sepsis in 3,961 patients admitted to hospital with a serious
infection found that measured LDL levels were associated with
increased risk of sepsis and admission to the intensive care
unit (Feng et al., 2019). However, after adjusting for clinical
factors and re-analysis in a genetic model, the association was
no longer present, suggesting that comorbidities accounted for
the observations seen in the unadjusted raw measures. This
supports the findings of our study which showed discordance
between the trend seen in the purely observational LDL levels
compared to the findings from the MR analysis, which is less
prone to confounding factors. Furthermore, it should be noted
that the MR effect size represents a lifelong exposure in contrast
to cross-sectionally measured LDL cholesterol which provides
a snapshot information influenced by intercurrent illness and
medical therapy.
Lipid metabolism plays a pivotal role in viral lifecycle
including replication, membrane homeostasis, endocytosis and
exocytosis (Abu-Farha et al., 2020). Indeed, previous experience
from SARS-CoV-1 infection indicated altered lipid metabolism
following recovery, suggesting a biological relationship (Wu
et al., 2017). Cholesterol depletion by drug treatment had been
shown to suppress an avian coronavirus (infectious bronchitis
virus) by disrupting the lipid rafts which enable cellular
entry (Guo et al., 2017). Another study investigating porcine
delta coronavirus found that pharmacological sequestration
effectively blocked viral attachment and internalization (Jeon
and Lee, 2018). These studies together with our own study
require further exploration and research assessing the potential
implications of LDL modification, such as with the use of statin
medications, for reducing susceptibility of developing COVID-19
or its severity.
Most previous observational studies have reported the
predictors of COVID-19 severity rather than COVID-19
susceptibility. One study (Gu et al., 2020) that investigated the
relationships between the clinical risk factors and COVID-19
susceptibility found positive associations between pre-existing
respiratory disease (OR: 3.28 [2.71–3.97]), circulatory disease
(OR: 2.46 [2.02–2.99]), type 2 diabetes (OR: 1.92 [1.53–
2.41]), chronic kidney disease (OR: 2.58 [1.98–3.37]), liver
disease (OR: 3.02 [2.18–4.17]) and autoimmune disease (OR:
2.55 [2.02–3.21]). While the effect sizes of the intermediate
phenotypes investigated in our study are generally smaller, it
is perhaps unsurprising given that diseases usually represent
extreme phenotypes.
Clinical Relevance
The implications of our findings are likely to be significant
in forming a risk assessment tool for those who are admitted
to hospital with COVID-19 and who may require more
intense monitoring and/or escalation of treatment at an
earlier stage. A recently reported COVID-19 risk assessment
tool for severe disease or mortality (Jankowski et al., 2020)
included BMI ≥ 35 kg/m2 as an independent risk factor.
Our data supports this but also highlights that the association
between BMI and COVID-19 susceptibility is monotonous.
Although the risk is highest for individuals in the highest
BMI category, those with moderately elevated BMI still
have non-negligible risk of COVID-19 even after accounting
for co-morbidities. Our findings may have an impact on
public health policy, whereby those who fall in the at-
risk obese category or those with extreme hyperlipidemia
in the general population may require more rigorous social
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distancing or shielding, particularly if a second wave or future
pandemics becomes a reality. Studies assessing the role for
cholesterol modification therapy during illness or hospital
admission could be undertaken to assess potential impact
on outcomes (Greenhalgh et al., 2020). Longer term and
wider emphasis on tackling obesity and dyslipidaemia, which
already features in many cardiovascular disease risk algorithms
(Khanji et al., 2016), through lifestyle advice and interventions
should be made a priority as part of a prevention strategy
(Khanji et al., 2018).
Strengths and Limitations
We believe this is the first study to use MR to evaluate
causality of obesity and cardiometabolic traits in the context of
COVID-19 susceptibility. The depth of data means that most
potential confounders and cardiometabolic parameters can
be assessed in a robust manner. We used large independent
datasets to obtain the effect estimates for genetic risk
scores which mitigated the risks of circular inferences or
overestimation in our results. The one-sample MR findings
were corroborated by two-sample MR, providing an additional
line of evidence.
There are certain limitations to our study. First, due to the
design of genetic risk scores constructed from predominantly
European discovery analyses and a small number of SARS-
CoV-2 positive minority ethnicities in the COVID-19 dataset
(n = 197), we confined our analyses to Caucasians which limits
the generalizability of our findings across other ethnicities.
This is especially important due to the disproportionate
impact of COVID-19 on non-White individuals. Future MR
studies should investigate the influence of cardiometabolic
risk factors on COVID-19 in populations of African and
other ancestries to better inform the public health policies.
Second, as the UK Biobank is a major contributor (∼56%)
of COVID-19 host genetics initiative, the data used in one-
sample and two-sample MR are not entirely independent
and the findings of our study need to be confirmed with
an independent validation dataset. Third, although we have
been able to assess causality for COVID-19 diagnosis based
on the available data, future analysis with additional test
result data along with detailed information on severity (such
ventilation requirement, thromboembolic complications) will
be crucial to contextualize our findings. With the on-going
enrichment of UK Biobank COVID-19 database alongside
the information provided by global consortia, it will soon
be possible to dissect these questions in a hypothesis-
driven manner.
CONCLUSION
This is the first study to identify the causal relationships
between BMI, LDL cholesterol and susceptibility to SARS-
CoV-2 infection. We found that the individuals in the top
quintiles of genetically determined BMI and LDL are especially
vulnerable. Altogether, our findings suggest that BMI should be
considered integral in the future risk assessment for COVID-19.
The influence of lipid metabolism on virus proliferation and the
role of LDL lowering medications for prophylaxis and treatment
of SARS-CoV-2 should be investigated in the future studies.
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